Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab

Hu TY, Vaidya VR, Asirvatham SJ

Vascular Health and Risk Management 2016, 12:35-44

Published Date: 17 February 2016